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INTRODUCTION
The pancreas forms from dorsal and ventral buds that appear
at the foregut-midgut junction starting at embryonic day (E)9.5
in the mouse. Over the subsequent 10 days of fetal
development, these two apparently uniform clusters of
epithelial cells differentiate into the cell types that compose the
adult pancreas: the endocrine cells of the islets of Langerhans,
the duct cells, and the exocrine cells (for reviews see Sander
et al. (1997); Slack (1995)).
The first detectable differentiated cells, starting at E9.5, are
glucagon-expressing a cells followed sequentially by other
islet cells: insulin-producing b cells, somatostatin-producing d
cells and pancreatic polypeptide-producing PP cells (Gittes and
Rutter, 1992; Herrera et al., 1991; Pictet et al., 1972; Rall et
al., 1973; Teitelman et al., 1993; Upchurch et al., 1994). Based
on this order of appearance, a variety of transgenic
experiments, and evidence that cells expressing more than
one endocrine hormone are present early in pancreatic
development, several models have been proposed to explain the
developmental lineage of endocrine cells (Alpert et al., 1988;
Herrera et al., 1994, 1991; Teitelman et al., 1993; Upchurch et
al., 1994). These models have in common the supposition that
the endocrine cells formed early in pancreatic development
function as progenitors of the mature islet cells found later.
This assumption has never been proved by direct lineage
tracing.
Alternatively, a population of undifferentiated precursor
cells may persist, allowing for new islet cell formation
throughout development. After E13, when ducts can first be
distinguished, new endocrine cells appear adjacent to, or even
embedded in the ducts (Githens, 1988; Herrera et al., 1991;
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Differentiation of early gut endoderm cells into the
endocrine cells forming the pancreatic islets of Langerhans
depends on a cascade of gene activation events controlled
by transcription factors including the basic helix-loop-helix
(bHLH) proteins. To delineate this cascade, we began by
establishing the position of neurogenin3, a bHLH factor
found in the pancreas during fetal development. We detect
neurogenin3 immunoreactivity transiently in scattered
ductal cells in the fetal mouse pancreas, peaking at
embryonic day 15.5. Although not detected in cells
expressing islet hormones or the islet transcription factors
Isl1, Brn4, Pax6 or PDX1, neurogenin3 is detected along
with early islet differentiation factors Nkx6.1 and Nkx2.2,
establishing that it is expressed in immature cells in the
islet lineage. Analysis of transcription factor-deficient mice
demonstrates that neurogenin3 expression is not dependent
on neuroD1/BETA2, Mash1, Nkx2.2, Nkx6.1, or Pax6.
Furthermore, early expression of neurogenin3 under
control of the Pdx1 promoter is alone sufficient to drive
early and ectopic differentiation of islet cells, a capability
shared by the pancreatic bHLH factor, neuroD1/BETA2,
but not by the muscle bHLH factor, MyoD. However, the
islet cells produced in these transgenic experiments are
overwhelmingly a cells, suggesting that factors other than
the bHLH factors are required to deviate from a default a
cell fate. These data support a model in which neurogenin3
acts upstream of other islet differentiation factors,
initiating the differentiation of endocrine cells, but
switching off prior to final differentiation. The ability to
uniquely identify islet cell precursors by neurogenin3
expression allows us to determine the position of other islet
transcription factors in the differentiation cascade and to
propose a map for the islet cell differentiation pathway.
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Pictet et al., 1972; Teitelman and Lee, 1987), suggesting that
either the duct cells themselves or some population of cells
harbored among the duct cells may function as precursors for
islet cells throughout development.
The morphologic changes that occur as endocrine cells
differentiate from precursors depend on sequential changes
in gene expression. Recent studies have focussed on the
underlying molecular events that control these changes in
gene expression. Gene disruption experiments in mice have
demonstrated the importance of several transcription factors of
the homeodomain family in islet cell differentiation. These
include Pax6 (Sander et al., 1997; St-Onge et al., 1997) and
Isl1 (Ahlgren et al., 1997), which are required for the normal
formation of all islet cell types, Pax4, which is involved in the
differentiation of b and d cells (Sosa-Pineda et al., 1997), and
Nkx6.1, which is required specifically for b cell formation (M.
Sander and M. German, unpublished data). The absence of
Nkx2.2 causes a reduction in a and PP cells, but also causes a
specific block in late steps of b cell differentiation (Sussel et
al., 1998). 
Cell-type-specific (class B) members of the basic helix-loop-
helix (bHLH) family of transcription factors play essential
roles in the development and maintenance of many
differentiated cell types. neuroD1/BETA2 is a class B bHLH
factor expressed in the pancreas and involved in islet cell
development and insulin gene transcription (Naya et al., 1995).
Although the targeted disruption of the neuroD1/BETA2 gene
in mice leads to a reduction in the endocrine cell mass at birth,
this is largely due to an increase in apoptosis: endocrine cell
formation is not blocked and insulin production continues in
the remaining b cells (Naya et al., 1997). The persistence of
islet cell genesis suggests that other bHLH proteins also may
contribute to islet cell differentiation during the development
of the pancreas.
The developing pancreas expresses a second, related bHLH
protein, neurogenin3 (Sommer et al., 1996b). Based on
experiments showing that early expression of neurogenin3 can
cause early differentiation of islet cells, and evidence that
neurogenin3 is not expressed in mature islet cells, Apelqvist et
al. (1999) have concluded that neurogenin3 is expressed in islet
cell progenitors and functions as a pro-endocrine gene driving
islet cell differentiation. However, other bHLH factors, such as
neuroD1/BETA2 were not tested in a similar fashion. Since
many class B bHLH factors can drive terminal differentiation
of a variety of cell types when expressed in the appropriate
precursors (Arnold and Winter, 1998; Jan and Jan, 1993; Lee,
1997; Sommer et al., 1996a), and it was not established
whether the cells normally expressing neurogenin3 are in the
islet cell lineage, it remains uncertain whether neurogenin3 is
the bHLH factor that normally functions as a pro-endocrine
gene in the developing pancreas. Furthermore, it is not clear
from these experiments whether neurogenin3 is sufficient to
drive the differentiation of all four islet cell types, since only
glucagon expression was examined.
Neurogenin3 is necessary, however, for the formation of all
four islet cell types, since mice carrying a homozygous targeted
disruption of the neurogenin3 gene lack any islet cells
(Gradwohl et al., 2000). In the early pancreatic bud,
neurogenin3 mRNA can be detected by in situ hybridization in
proliferating cells expressing the homeodomain protein Pdx1,
but not in hormone-expressing cells, while neuroD1 mRNA is
detected in a non-replicating cell population that includes
mature hormone-expressing cells (Jensen et al., 2000).
Together, these results have led to the hypothesis that
neurogenin3 lies upstream of neuroD1 in the pathway of islet
cell differentiation, a conclusion that is supported by recent
evidence that neurogenin3 can activate the neuroD1 promoter
(Huang et al., 2000).
In the present study, we clarify the position of neurogenin3
in the hierarchy of islet transcription factors. We demonstrate
by degenerate RT-PCR and in situ hybridization that islet cells
and the developing pancreas express a broad group of class B
bHLH genes, among the most abundant being neurogenin3
(ngn3), neuroD1/BETA2, Mash1 and neuroD4/Math3.
Immunohistochemical analysis reveals that neurogenin3 is
indeed co-expressed with some markers of differentiating islet
cells, including the b cell differentiation factor Nkx6.1, thus
establishing that neurogenin3 marks islet cell precursors. In an
experiment similar to that of Apelqvist et al. (1999), we
confirm that neurogenin3 can drive the early differentiation of
islet cells, but also find that neuroD1/BETA2 shares this
capacity. However, these transgenic experiments only produce
glucagon-expressing a cells. Thus other signals in addition to
the pro-endocrine bHLH factors are required to develop the full
spectrum of islet cell types. Together with earlier studies, these
results provide the framework for a more detailed map of the
differentiation pathway for pancreatic islet cells. 
MATERIALS AND METHODS
RT-PCR
Total cellular RNA was extracted from rat islets and mRNA was
prepared from a TC, b -TC3, mPAC and 266 cells using the
RNaqueous extraction kit (Ambion) and DNase I treatment to remove
contaminating genomic DNA. Oligo(dT)-primed reverse transcription
of RNA was carried out for 1 hour at 42°C using Superscript II
(Gibco). First strand cDNA served as a template for PCR
amplification as previously described (Sommer et al., 1996b) using
Taq polymerase (Fisher) and the following degenerate primers
derived from the helix 1 and the loop of the conserved bHLH
encoding region of the neural class B bHLH genes (5¢ primer:
cgggatccAAT/CGA/CIC/AGIGAA/GC/AGIAAT/CC/AGIA/GT, 3¢
primer: cggaattcAG/AIGTT/CTCIAT/CT/CTTIG/CA/TIAT/G/AT/
CTT). PCR was carried out in a DNA Thermal Cycler (Perkin-Elmer)
for eight cycles with a denaturation step at 94°C for 1 minute,
annealing at 43°C for 1 minute and extension at 72°C for 1 minute,
followed by an additional 40 cycles with the annealing temperature
raised to 55°C. The Taq polymerase was added at 94°C during the
first cycle. The 127 bp PCR product was purified from a NuSieve
agarose gel by Quiaquick (Quiagen), subjected to a second round of
PCR (40 cycles of 1 minute at 90°C, 1 minute at 5°C, and 1 minute
at 72°C), digested with EcoRI and BamHI, and cloned into the
pBlueScript (KS)+ vector (Stratagene). In total, 107 clones were
characterized and identified by sequencing with the Sanger dideoxy
method. 
In situ hybridization
For RNA in situ hybridization analysis of paraffin sections (5 m m),
embryos and pancreases were processed, sectioned and hybridized
with digoxigenin-labeled riboprobes as described by Neubuser et al.
(1995) with some modifications. Digoxigenin-labeled sense and
antisense riboprobes were detected with alkaline phosphatase-coupled
anti-digoxigenin antibodies using BM purple (Boehringer Mannheim)
as color substrate. Riboprobes used in this study were as follows: ngn1
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(Ma et al., 1996), ngn2 and ngn3 (Sommer et al., 1996b), neuroD1
(Lee et al., 1995), and Mash1 (Guillemot et al., 1993).
To obtain a neuroD4/Math3 probe (Takebayashi et al., 1997), a l -
ZAP (Stratagene) cDNA library prepared from the mouse insulinoma
cell line b -TC3 was screened by hybridization with the PCR product
encoding neuroD4. From positive clones, a full length neuroD4 cDNA
was selected and confirmed by sequencing with the Sanger dideoxy
method.
Immunohistochemical and immunofluorescence assays
Immunohistochemistry and immunofluorescence assays were
performed on paraffin sections as described previously (Sander et al.,
1997). Primary antibodies employed in these assays: mouse anti-
insulin antibody (Sigma) diluted 1:10000; guinea pig anti-insulin
1:10000 (Linco, St. Charles, MI); mouse anti-glucagon 1:10000
(Sigma); guinea pig anti-glucagon 1:10000 (Linco); guinea pig anti-
peptide YY (kindly provided by G. Aponte (Upchurch et al., 1994))
1:800; rabbit anti-Pax6-QNR antiserum 11 (kindly provided by S.
Saule, Institut Pasteur, Lille, France) directed against the paired
domain of quail PAX6 (Turque et al., 1994), diluted 1:4000; mouse
anti-Isl1 (Developmental Hybridoma Bank) 1:200; monoclonal mouse
anti-Nkx2.2 (kindly provided by T. Jessel) 1:50; rabbit anti-Nkx6.1
(Sussel et al., 1998) 1:6000; rabbit anti-Brn4 (kindly provided by M.
G. Rosenfeld (Schonemann et al., 1995) 1:100; monoclonal mouse
anti-skeletal muscle myosin heavy chain clone MF20 (Developmental
Hybridoma Bank) 1:100; monoclonal mouse anti-smooth muscle
actin clone 1A4, cy3-conjugated (Sigma) 1:200; mouse anti-PCNA
and Ki-67 (Pharmigen) 1:4000. Secondary antibodies were used as
described previously (Sander et al., 1997). 
Neurogenin3 antigen was produced by inserting the coding
sequence for the amino-terminal 95 amino acids from mouse
neurogenin3 downstream of the glutathione S-transferase coding
sequence in the pGEX-2T vector (Pharmacia). The resulting fusion
protein was purified from E. coli and injected into rabbits and guinea
pigs. 1:5000 (rabbit) or 1:4000 (guinea pig) dilutions were used for
staining, and preimmune sera from both animals gave no staining at
the same concentrations. Pdx1 antigen was produced by inserting the
coding sequence for the carboxy-terminal 80 amino acids from mouse
IPF1 downstream of the glutathione S-transferase coding sequence in
the pGEX-2T vector (Pharmacia). The resulting fusion protein was
purified from E. coli and injected into rabbits and guinea pigs. 1:4000
dilutions of the guinea pig antiserum were used for staining, and
preimmune sera gave no staining at the same concentrations.
For immunofluorescence assays, Cy3- (Jackson ImmunoResearch
Laboratories), Texas Red- and FITC-conjugated (Cappel) goat anti-
rabbit, anti-guinea pig and anti-mouse were applied at a 1:200
dilution. Fluorescence was visualized with a Zeiss axioscope and a
Leica confocal microscope.
Transgenic mice
The Pdx1 promoter vector pBAT.PD17 was constructed by inserting
the mouse Pdx1 promoter (a 4.4 kb XbaI-SmaI fragment from the
mouse Pdx1 gene containing the transcription start site and promoter
(Apelqvist et al., 1997; Wu et al., 1997)) and the human b -globin gene
first intron upstream of the pBAT polylinker (German et al., 1992) and
the SV40 late gene polyadenylation signal. A 663 bp DNA fragment
encoding full length mouse ngn3 cDNA was obtained by PCR from
the mouse genomic neurogenin3 clone (Sommer et al., 1996b) and
inserted into the pBAT.PD17 polylinker. The neuroD1/BETA2 vector
was constructed by cloning into pBAT.PD17 a 1.7 kb DNA fragment
encoding the full length mouse cDNA (Lee et al., 1995) extending
from the start codon through the 3¢ UTR. The MyoD vector was
constructed by cloning into pBAT.PD17 a 1 kb DNA fragment
encoding the full length mouse cDNA (Davis et al., 1987) extending
from the start codon through the first 63 bp of the 3 ¢ UTR. 
The vectors were linearized and purified, and transgenic mice were
generated by pronuclear injection (1.5 ng/ m l) into F1 hybrid oocytes
from C3Fe/B6 parents as described by Hogan et al. (1994). Genotypes
were determined by PCR analysis of genomic DNA from tail biopsies.
The primers used were: 5 ¢ TGGAGAACTGTCAAAGCGATCTG
(Pdx1 primer for 5 ¢ ) and 5 ¢ CACATGCCCAGTTTCTATTGGTC
(human b -globin intron for 3 ¢ ).
Embryos were harvested at E12.5 or E18.5. A total of 6 Pdx1-ngn3
animals were examined at E12.5, and 10 at E18.5. A total of 5 Pdx1-
neuroD1 animals were examined at E12.5, and 10 at E18.5. As is
common in independent transgenic founders and has been seen
previously in transgenic animals produced with the Pdx1 promoter
(Apelqvist et al., 1997, 1999), these animals display a spectrum of
phenotypes. At E18.5, pancreatic size varied in both groups of
transgenics, from normal to the extreme micro-pancreas shown in Fig.
8. The extreme micro-pancreas was observed in two animals in each
group. Less variation was observed at E12.5, when the majority of
pancreases from both groups contained more glucagon-expressing
cells than their littermates. Those phenotypes observed in multiple
independent founders are reported. The liver in the Pdx1-ngn3
transgenic animal in Fig. 8A appears reduced in size; this abnormality
was not observed in other transgenics. The transgenic animals were
not grossly abnormal in size. Only a single control Pdx1-MyoD
transgenic was sectioned and stained at E18.5; it is shown in Fig. 9.
RESULTS
Expression of bHLH genes in pancreatic cell lines
and islets
Expression of mRNA encoding class B bHLH proteins was
detected using a non-quantitative method of RT-PCR with
degenerate oligonucleotide primers derived from the conserved
bHLH-encoding region of NeuroD1/BETA2-related genes (Ma
et al., 1996). cDNA was prepared from purified adult rat islets
and from four mouse cell lines: the b cell line b -TC3 (Efrat et
al., 1988), the a cell line a -TC1.6 (Hamaguchi and Leiter,
1990), the pancreatic ductal cell line mPAC (Yoshida and
Hanahan, 1994), and the pancreatic exocrine cell line 266
(Ornitz et al., 1985). The PCR products encode 9 distinct
sequences including NeuroD1/BETA2 (Lee, 1997; Naya et al.,
1995), Mash1 (Guillemot et al., 1993), NeuroD2 (McCormick
et al., 1996), neuroD4/Math3 (Takebayashi et al., 1997),
neurogenins (ngn)1, 2 and 3 (Gradwohl et al., 1996; Ma et al.,
1996; Sommer et al., 1996b), Mist1 (Lemercier et al., 1997),
and meso1/scleraxis (Blanar et al., 1995; Cserjesi et al., 1995)
Table 1. Degenerate PCR of islet and pancreatic cell line
cDNA*
Rat islets b TC3 a TC1.6 mPAC 266
neuroD1/BETA2 3 6 6 1
neuroD2 2 2
neuroD4/Math3 5 4 3 2 7
neurogenin1 4 6 2 1
neurogenin2/Math4A 2 1
neurogenin3 4 4 7 4
Mash1 1
mist 2 2 3
meso1/scleraxis 1
non-bHLH 2 3 11
*RT-PCR was performed using the degenerate oligonucleotides described
in the Materials and Methods section with RNA purified from the cell types
indicated. The products were subcloned and sequenced. Each number
indicates how many copies of that cDNA were sequenced from the cells
shown. All of the sequences that were obtained are included.
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(Table 1). Ngn3 and NeuroD4 were found in all the pancreatic
endocrine cell lines and in rat islets; NeuroD4 was also found
in the exocrine cell line. Only NeuroD1/BETA2, ngn3 and
mist1 were previously known to be expressed in the pancreas
(Apelqvist et al., 1999; Naya et al., 1997; Naya et al., 1995;
Sommer et al., 1996b). Although degenerate PCR
amplification does not produce quantitative information
regarding expression level, these data provide a set of bHLH
cDNAs from pancreatic cells for further analysis of expression
levels and patterns. 
Expression of bHLH factors in the pancreas in vivo
To determine the expression pattern in vivo of the bHLH
factors detected by RT-PCR, in situ hybridization studies of the
developing mouse pancreas were performed. Consistent with
previous studies (Apelqvist et al., 1999; Sommer et al., 1996b),
this analysis detects high expression levels of ngn3 and
neuroD1 at E12.5 and E15.5 (Fig. 1 and data not shown). Low
expression of Mash1 and neuroD4/Math3 can be detected at
E15.5 (Fig. 1). At E12.5 neither Mash1 nor neuroD4/Math3
can be detected in the pancreas, although Mash1 can be
detected in scattered cells surrounding the pancreas (data not
shown), probably due to expression in developing enteric
neurons (Lo et al., 1991). Significant expression was not
detected for neurogenins 1 and 2, or neuroD2 at any date (data
not shown).
Using polyclonal antisera, ngn3 can be detected as early as
E11.5 in a few epithelial cells of the pancreatic bud, at E15.5
it reaches a peak of expression, decreases at E18.5, and is
undetectable in the adult pancreas (Fig. 2 and data not shown).
Although we did not detect ngn3 protein in the pancreas
prior to E11.5, ngn3 mRNA has been detected by in situ
hybridization in scattered cells in the pancreatic bud as early
as E9.5 (Apelqvist et al., 1999; Jensen et al., 2000). At E15.5
ngn3 is detected in the nuclei of scattered ductal cells and
occasional periductal cells. Immunofluorescent double labeling
at E15.5 shows no co-staining with several endocrine cell
products, including insulin, glucagon, somatostatin, pancreatic
polypeptide, islet amyloid polypeptide and peptide YY (Fig. 3
and data not shown), suggesting that if ngn3 plays a role in
islet cell development, it is switched off prior to final
differentiation.
Immunofluorescent double labeling was performed for ngn3
and two proteins expressed in islet cell precursors: Nkx6.1, a
b cell homeodomain transcription factor (Jensen et al., 1996;
Rudnick et al., 1994); and Nkx2.2, a homeodomain factor
expressed in all a , b , and PP cells, and required for normal b
cell differentiation (Sussel et al., 1998). At E15.5 Nkx6.1 is co-
expressed in 30-50% of cells expressing ngn3, and Nkx2.2 is
expressed in 70-80% of cells expressing ngn3 (Fig. 4). These
data demonstrate that ngn3 expression marks precursor
endocrine cells, and is absent from differentiated endocrine
cells.
ngn3 is not co-expressed, however, with two homeodomain
transcription factors normally present within the pancreatic
epithelium only in fully differentiated islet cells: the LIM-
homeodomain factor Isl1 (Fig. 4), which is required for the
differentiation of all islet cells (Ahlgren et al., 1997); and the
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Fig. 1. Expression of bHLH genes at E15.5. In situ hybridization studies in E15.5 fetal mouse pancreas are shown for (A) ngn3, 
(B) NeuroD1/BETA2, (C) Mash1, (D) NeuroD4 and (E) NeuroD2. 200· magnification. Only pancreatic tissue is shown.
Fig. 2. Expression of
neurogenin3 in the developing
mouse pancreas.
Immunohistochemical staining
for neurogenin3 using rabbit
anti-mouse neurogenin3
(1:5000) and peroxidase labeled
goat anti-rabbit IgG (1:1000) in
fetal mouse pancreas (A) at
E11.5, (B) at E12.5, (C) at E15.5
and (D) at E18.5 (200 ·
magnification). Arrows in A and
D indicate nuclei expressing
ngn3. Inset in C at 400·
magnification shows nuclei
staining for ngn3 in cells lining
a duct.
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paired homeodomain factor Pax6 (data not shown), which is
involved in islet formation and islet hormone synthesis (Sander
et al., 1997; St-Onge et al., 1997). At E15.5 ngn3 is also not
co-expressed with Brn4, a Pou-homeodomain transcription
factor found in a cells (Hussain et al., 1997), or with Pdx1, a
homeodomain transcription factor largely restricted to b and d
cells at this stage (Fig. 4). These results place these four factors
late in the differentiation pathway.
Pancreatic expression of ngn3 in mice lacking islet
transcription factors
To place ngn3 in the hierarchy of transcription factors involved
in islet development, animals with targeted disruptions or
mutations of several islet transcription factor genes were
examined for ngn3 expression. Mice homozygous for a
targeted disruption of the NeuroD1/BETA2 or Mash1 genes
were examined at E18.5, and Nkx6.1 and Nkx2.2 null animals
were examined at E15.5 and E18.5. In all of these animals,
ngn3 is still expressed at levels equivalent to the levels in wild-
type littermates (Fig. 5, and data not shown). ngn3 is also
expressed in pancreases of embryos homozygous for the Pax6
mutant allele, SeyNeu (loss of function mutation) (Fig. 5).
The pancreases of mice lacking Mash1 were also examined
for differences in islet development. At E18.5, no obvious
abnormalities can be detected in islet morphology or the
expression patterns of the islet hormones insulin, glucagon,
somatostatin and PP (Fig. 6 and data not shown).
The expression levels of ngn3 in these mutant animals
demonstrate that its expression is not dependent on any one of
these transcription factors, and together with the co-staining
data suggest a function upstream of Nkx6.1, Nkx2.2 and Pax6.
Transgenic expression of bHLH factors 
To further investigate the function of ngn3, transgenic mice
over-expressing ngn3 early during development were created
using the Pdx1 promoter to drive expression of a mouse ngn3
cDNA in pancreatic progenitor cells. Pdx1 is a homeodomain
transcription factor expressed in the gut endoderm near the
foregut-midgut junction prior to formation of the pancreas
(E8.5). As the gut matures, scattered expression of Pdx1
persists in the duodenum and antral stomach. When the dorsal
and ventral pancreatic buds form (E9.5-E10.5), Pdx1 then is
expressed broadly in the epithelial cells forming the pancreatic
bud, but is inactivated in the few endocrine cells (mostly a cells
with rare b cells) that differentiate at this stage. Starting around
E13, Pdx1 expression becomes limited to b cells and d cells
(Guz et al., 1995; Offield et al., 1996; Ohlsson et al., 1993;
Oster et al., 1998). The portion of the mouse Pdx1 promoter
used in these studies is sufficient to drive the expression of
linked genes in the same pattern (Apelqvist et al., 1997; Gerrish
et al., 2000; Wu et al., 1997).
Founder mice were analyzed at E12.5 and E18.5. Similar to
a previous report (Apelqvist et al., 1999), at E12.5 in mice
over-expressing ngn3, there is a marked increase in the number
of glucagon-expressing cells in the pancreatic buds relative to
wild-type litter mates, with most of the cells converted to an a
cell fate (Fig. 7). Glucagon staining can also be detected in a
few cells lining the duodenum near the pancreas (Fig. 7D) and
the antral stomach in some transgenic animals indicating that
expression of ngn3 in areas of Pdx1 expression outside the
pancreas (Offield et al., 1996) can induce the development of
ectopic endocrine cells.
Transgenic animals were examined for ectopic expression of
the ngn3 transgene, but none was detected. This result is not
surprising since the Pdx1 promoter driving the ngn3 transgene
Fig. 3. Double immunofluorescence staining in fetal mouse pancreas
at E15.5 with (A) with anti-insulin serum (cy3 label, red) and anti-
ngn3 serum (fluorescein label, green); (B) anti-glucagon serum (cy3
label, red) and anti-ngn3 serum (fluorescein label, green), and 
(C) anti-peptide YY serum (cy3 label, red) and anti-ngn3 serum
(fluorescein label, green). Photomicrographs imaged confocally.
400· magnification.
Fig. 4. Transcription factor co-expression in developing islet cells. Double immunofluorescence staining is shown at E15.5 with (A) anti-
Nkx2.2 serum (cy3 label, orange) and anti-ngn3 serum (fluorescein label, green), (B) anti-Nkx6.1 serum (fluorescein label, green) and anti-
ngn3 serum (cy3 label, orange), (C) anti-Isl1 serum (cy3 label, orange) and anti-ngn3 serum (fluorescein label, green), (D) anti-Brn4 serum
(fluorescein label, green) and anti-ngn3 serum (cy3 label, orange), and (E) anti-Pdx1 serum (cy3 label, orange) and anti-ngn3 serum
(fluorescein label, green). Photomicrographs in B,C, and D were confocally imaged. Note the yellow staining in the co-staining nuclei in A and
B. 400 · magnification.
A B C
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is not active in a cells, the predominant cell type in these
pancreases (Gerrish et al., 2000; Wu et al., 1997). We presume
that ngn3 is expressed in progenitor cells at an early stage
(Offield et al., 1996), but is extinguished in the differentiated
cells examined at E12.5. To test the possibility that the increase
in a cells is due to increased proliferation, E12.5
transgenic pancreas was tested for the presence of
markers for dividing cells, PCNA and Ki-67, by
immunohistochemistry; the a cells did not express
these proliferation markers (Fig. 7F and data not
shown). Given the premature increase in a cells in
conjunction with the depletion of undifferentiated
precursor cells in the E12.5 pancreas, we conclude that
the increase in the a cell population results from
premature differentiation of pancreatic epithelial cells
expressing the ngn3 transgene into a cells.
By E18.5, transgenic animals show a dramatic
decrease of the size of the pancreas (Fig. 8A),
consistent with the depletion of precursors due to
premature differentiation into a non-dividing
population of mature cells. At E18.5 the fraction of
endocrine cells is grossly increased, and this increase
can be accounted for by an increase in the proportion
of glucagon-expressing cells (Fig. 9). In addition, the
glucagon-positive cells are no longer limited to the
periphery of islets as in the wild-type littermates, but
now fill out entire islets. Double immunofluorescence
labeling for glucagon and insulin confirms the
predominance of glucagon over insulin, but does not
detect any cells expressing both hormones (Fig. 9I).
Transgenic mouse embryos expressing NeuroD1/
BETA2 under control of the Pdx1 promoter were
also examined at E12.5 and E18.5. Like the ngn3
transgenic animals, these animals demonstrate early
differentiation of endocrine cells, with a marked
reduction or absence of duct and exocrine structures
(Figs 7C, 8B, 9E,F). Again the overwhelming majority of
endocrine cells express glucagon.
Finally, to determine the specificity of the effects of ngn3
and NeuroD1/BETA2 on pancreas development, transgenic
mice over-expressing MyoD, a class B bHLH gene normally
expressed during muscle development and not normally
expressed in the pancreas (Sassoon et al., 1989), were
examined. In common with ngn3 and neuroD1/BETA2,
transgenic expression of MyoD results in a decrease in the size
of the pancreas at E18.5; but there is a decrease in endocrine
cells, especially insulin-expressing cells (Fig. 9G,H). In
addition, MyoD expression results in the formation of strands
of multinucleated cells that express the muscle-specific
proteins, smooth muscle actin (a marker also found in
embryonic skeletal muscle; Woodcock-Mitchell et al., 1988)
and skeletal muscle myosin heavy chain (Fig. 9J and data not
shown).
DISCUSSION
These studies demonstrate that the developing pancreas and
mature islet cells express a variety of class B bHLH genes. Not
all of these genes are expressed at substantial levels as gauged
by in situ hybridization, nor are they all expressed at the same
time. None the less, the proteins encoded by some of these
genes, especially the multiple members of the neurogenin and
neuroD family (Lee, 1997; Sommer et al., 1996b), are
remarkably closely related; and their overlapping expression
suggests a significant degree of redundancy.
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Fig. 5. Neurogenin3 expression in mutant mice. Immunohistochemical
staining for neurogenin3 is shown at E15.5 (A-C) and E18.5 (D-F) in the
pancreas of mice with the following transcription factor mutations: 
(A) Nkx2.2+/+, (B) Nkx2.2- /- , (C) SeyNeu/SeyNeu (Pax6 null mutation), 
(D) Mash1+/+, (E) Mash1- /- , (F) neuroD1/BETA2 - / - as positive control. 400·
magnification. In each panel, neurogenin3 can be detected in the nuclei of cells
scattered along a large duct within the pancreatic parenchyma.
Fig. 6. Insulin and glucagon expression in mice lacking Mash1.
Immunohistochemical staining is shown for insulin (A,C) and
glucagon (B,D) in pancreases at E18.5 from Mash1+/+ (A,B) and
Mash1- / - (C,D) animals. (200 · magnification). In each panel, the
arrow indicates a forming islet, with insulin-expressing b cells in the
center surrounded by glucagon-expressing a cells.
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The presence of multiple bHLH factors in the pancreas is
not surprising, since a similar degree of redundancy has been
noted in the development and maintenance of other organ
systems such as muscle or nervous system (Jan and Jan, 1993;
Molkentin and Olson, 1996). This redundancy could explain
the modest phenotype of mice lacking NeuroD1/BETA2 (Naya
et al., 1997). However, although neurogenin3 is present in
the NeuroD1/BETA2 null animals, its expression is neither
increased nor prolonged relative to the wild-type littermates,
indicating that neurogenin3 does not compensate for the
absence of neuroD1/BETA2. 
Differences in the pattern and timing of expression of the
bHLH genes in the developing pancreas suggests that their
functions are not completely redundant, and they may have
overlapping but distinct roles in the gene expression events
controlling differentiation. The Mash genes are the mammalian
homologues of the Drosophila proneuronal achaete-scute
genes (Johnson et al., 1990), and in some examples Mash1 lies
upstream of members of the neurogenin and neuroD gene
families in the cascade of transcription factors controlling
mammalian neural development (Cau et al., 1997; Lee, 1997).
In the pancreas, however, Mash1 is not required either for
expression of neurogenin3 or for endocrine differentiation. The
absence of a pancreatic phenotype in animals lacking Mash1
could indicate the presence of functionally redundant factors
at this step in pancreatic development, but its level of
expression as indicated by in situ hybridization suggests that
Mash1 may not be an important regulator of pancreatic
endocrine cell differentiation. 
Instead of Mash1, neurogenin3 or neuroD1 may be the
furthest upstream members of the class B bHLH family and
fill the role of the proneuronal genes in islet development.
Members of both the neurogenin and neuroD families can drive
vertebrate neurogenesis (Lee et al., 1995; Ma et al., 1996),
and both neurogenin3 and neuroD1 can individually drive
endocrine cell genesis. But which of these genes fills this role
in vivo? The phenotype of animals lacking neuroD1 or Mash1
and its expression pattern suggest that neurogenin3 is the
earliest pro-endocrine bHLH gene expressed. In contrast,
animals lacking neurogenin3 fail to express neuroD1
(Gradwohl et al., 2000), suggesting that the role of neurogenin3
may be to activate neuroD1, which in turn directs endocrine
cell differentiation, similar to the proposed role of neurogenins
Fig. 7. Expression of islet hormones in transgenic
mice at E12.5. Immunohistochemical staining is
shown for glucagon in pancreases of a non-
transgenic littermate (A) and transgenic fetuses
expressing ngn3 (B) or neuroD1/BETA2 (C) (200 ·
magnification). (D) Immunohistochemical staining
for glucagon in the adjacent duodenum from the
animal in B demonstrates scattered glucagon-
expressing cells in the gut epithelium (400 ·
magnification). (E,F) Serial sections of the
pancreas and surrounding tissue from a transgenic
fetus expressing ngn3 showing
immunohistochemical staining for glucagon 
(E) and the proliferating cell nuclear antigen
PCNA (F) (150 · magnification). The glucagon
expressing pancreatic epithelium in E is outlined
with a dashed line that is superimposed on the
serial section in F.
Fig. 8. Gross anatomy of the gut and associated organs of transgenic
animals at E18.5 over expressing (A) ngn3 or (B) neuroD1 under the
control of the Pdx1 promoter. Non-transgenic littermates are shown
at the right in each panel (wt). Arrows points to the following organs:
liver (L), stomach (St), spleen (Sp), and pancreas (P). Reduced
pancreatic tissue is not visible in the transgenic animals. Reductions
in the stomach and small intestine are also visible in the transgenic
animals.
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in initiating neuroD expression during neural development
(Lee, 1997; Ma et al., 1996). Although not the only possible
explanation, the expression and transgenic studies are
consistent with this model, as shown in Fig. 10. Recent studies
of the mouse neuroD1 promoter also support the conclusion
that neurogenin3 directly activates neuroD1 expression (Huang
et al., 2000). 
The transgenic animal experiments demonstrate that
neurogenin3 and neuroD1/BETA2 drive endocrine
differentiation; but the cell fate induced by ectopic ngn3
expression in these experiments is predominantly or
exclusively a cells. Although it is possible that endogenous
neurogenin3 only drives a cell differentiation, the co-
expression of neurogenin3 with beta cell transcription factor
Nkx6.1 during normal development strongly suggests the
involvement of neurogenin3 in the differentiation of other
pancreatic endocrine cells. In addition, the recent targeted
disruption of the neurogenin3 gene in mice demonstrates that
neurogenin3 is required for the formation of all four endocrine
cell lineages (Gradwohl et al., 2000). Alternatively, the
predominance of a cells in the transgenic animals could result
from the abnormally early and broad expression of the
transgenes under control of the Pdx1 promoter. By E12.5 in the
transgenic animals, the majority of cells in the pancreas have
already differentiated, and the marked reduction in the size of
the pancreas at E18.5 demonstrates that little further growth
occurs. Normally in non-transgenic mice very few insulin-
producing cells appear in the pancreas prior to E13,
presumably due to the lack of factors such as Pax4 (Smith et
al., 1999) that are required for b cell differentiation (Sosa-
Pineda et al., 1997). These results suggest a model in which a
cells are the default result of neurogenin3 expression, and
additional signals are required to deviate neurogenin3-
expressing progenitor cells to alternate cellular fates such as b
cells (Fig. 10).
The ability to identify endocrine precursor cells based on
neurogenin3 expression allows us to refine prior models of the
cascade of transcription factors controlling islet cell
differentiation (Edlund, 1998; Guz et al., 1995; Jensen et al.,
2000; St-Onge et al., 1999). Combining our data with previous
genetic and functional studies, we propose a model in Fig. 10
that places many of the key islet transcription factors on a map
of islet cell differentiation. Rigorous genetic proof is lacking
for some points on the map, but hopefully this proposed model
will provide a basis for further studies and a frame work for
future refinements.
It must be noted that our data is not in agreement with
previous proposals that early cells expressing glucagon, PP or
peptide YY function as precursors of other islet cells (Alpert
et al., 1988; Herrera et al., 1994, 1991; Teitelman et al., 1993;
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Fig. 9. Expression of islet hormones in transgenic mice at E18.5.
Immunohistochemical staining is shown for insulin (A,C,E,G) and
glucagon (B,D,F,H) in pancreases of a wild-type fetus (A,B) and
transgenic fetuses expressing ngn3 (C,D), neuroD1/BETA2 (E,F) or
MyoD (G,H) under the control of the Pdx1 promoter. E and F show a
single large duct with a small clump of remaining pancreatic tissue
staining predominantly for glucagon. (I) Immunoflourescent staining
for glucagon (cy3 label, orange) and insulin (fluorescein label, green)
in the pancreas of a transgenic fetus expressing ngn3 at E18.5. 
(J) Immunoflourescent staining for smooth muscle actin (cy3 label,
orange) and amylase (fluorescein label, green) in the pancreas of a
transgenic fetus expressing MyoD, at E18.5. (200 · magnification).
Only pancreatic tissue is shown, with the exception of E and F which
















Fig. 10. Model for the role of ngn3 in endocrine differentiation in the
mouse pancreas. The proposed position for each transcription factor
is based on its timing of expression, timing of predominant
functional role, or both. Clearly some factors function at several
steps, but a single step is shown for simplicity. 
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Upchurch et al., 1994). In the transgenic experiments the
dramatically increased early pool of a cells does not result in
the further differentiation of these cells to other islet cell types,
even by E18.5. In the normal, non-transgenic animals, the
absence of cells co-expressing multiple islet hormones during
the peak of neurogenin3 expression and endocrine cell
neogenesis (E15) suggests that islet cell type fate is determined
prior to hormone expression. This conclusion is supported by
the presence of the b cell transcription factor Nkx6.1 in some
neurogenin3-expressing precursors. Nkx6.1 is never seen
in glucagon-expressing cells (M. Sander and M. S. G.,
unpublished data; Oster et al., 1998), suggesting that these cells
co-expressing neurogenin3 and Nkx6.1 are already determined
to follow a b cell fate. We propose that both b cells and a
cells independently derive from a non-hormone-expressing
precursor that expresses neurogenin3, and islet cell type
decisions are made prior to the expression of hormones.
This model does not address whether neurogenin3-
expressing cells represent a sustained stem cell population, or
a transient state through which individual progenitor cells
progress. By definition, stem cells regenerate themselves while
producing new differentiated cells. In contrast, the transgenic
experiments show that neurogenin3 forces cells to differentiate
and does not allow cells to remain in the undifferentiated state.
This does not mean that there are no endocrine stem cells, but
rather that if such cells exist, they do not express neurogenin3.
The massive early differentiation of endocrine cells in the
transgenic experiments demonstrates that prior to E13 most
of the epithelial cells of the pancreas retain the capacity
to differentiate into endocrine cells. The appearance of
neurogenin3-expressing cells among the duct cells after E13
suggests that the ability to respond to neurogenin3 and to
differentiate into endocrine cells persists in the duct cells after
E13, and that duct cells may effectively function as endocrine
stem cells. 
Do duct cells in the mature pancreas retain the capacity to
differentiate into endocrine cells? Experiments in pancreatic
regeneration suggest that they may (Slack, 1995). If the adult
duct cells can respond to the pro-endocrine bHLH genes, then
in combination with other signals these genes potentially could
be used to induce new b cell formation to replace the b cells
lost to autoimmune destruction in individuals with type 1
diabetes.
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